iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Tables)

9 Months Ended

Mar. 31, 2023


	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2023		2022		2023		2022
Basic and diluted numerator:

Net loss attributable to iBio, Inc. from continuing operations	$	(6,279)	$	(6,746)	$	(24,379)	$	(19,125)
Preferred stock dividends – iBio CMO Preferred Tracking Stock		—		—		—		(88)
Net loss available to iBio, Inc. stockholders from continuing operations	$	(6,279)	$	(6,746)	$	(24,379)	$	(19,213)

Net loss available to iBio, Inc. stockholders from discontinued operations	$	(1,015)	$	(5,644)	$	(34,598)	$	(14,124)

Net loss available to iBio, Inc. stockholders - total	$	(7,294)	$	(12,390)	$	(58,977)	$	(33,337)

Basic and diluted denominator:

Weighted-average common shares outstanding		13,184		8,719		10,592		8,719

Per share amount - continuing operations	$	(0.47)	$	(0.77)	$	(2.30)	$	(2.20)
Per share amount - discontinued operations	$	(0.08)	$	(0.65)	$	(3.27)	$	(1.62)
Per share amount - total	$	(0.55)	$	(1.42)	$	(5.57)	$	(3.82)


	March 31,
	2023	2022

	(in thousands)
Stock options	457	625
Restricted stock units	443	22
Warrants	5,948	52
Shares excluded from the calculation of diluted loss per share	6,848	699